Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Equity (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Return on Equity for 15 consecutive years, with 0.43% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Equity rose 25.0% year-over-year to 0.43%, compared with a TTM value of 0.43% through Sep 2025, up 25.0%, and an annual FY2024 reading of 0.62%, down 10.0% over the prior year.
  • Return on Equity was 0.43% for Q3 2025 at China Pharma Holdings, up from 0.54% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.39% in Q1 2021 and bottomed at 1.12% in Q4 2022.
  • Average Return on Equity over 5 years is 0.64%, with a median of 0.59% recorded in 2023.
  • The sharpest move saw Return on Equity soared 199bps in 2021, then plummeted -59bps in 2022.
  • Year by year, Return on Equity stood at 0.53% in 2021, then plummeted by -111bps to 1.12% in 2022, then soared by 59bps to 0.45% in 2023, then tumbled by -46bps to 0.66% in 2024, then surged by 35bps to 0.43% in 2025.
  • Business Quant data shows Return on Equity for CPHI at 0.43% in Q3 2025, 0.54% in Q2 2025, and 0.62% in Q1 2025.